» Authors » Gerd Ritter

Gerd Ritter

Explore the profile of Gerd Ritter including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 135
Citations 7262
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta A, Budhu S, Fitzgerald K, Giese R, Michel A, Holland A, et al.
Commun Biol . 2021 Nov; 4(1):1296. PMID: 34789823
TGFβ is a potential target in cancer treatment due to its dual role in tumorigenesis and homeostasis. However, the expression of TGFβ and its inhibition within the tumor microenvironment has...
2.
Gombos R, Gonzalez A, Manrique M, Chand D, Savitsky D, Morin B, et al.
PLoS One . 2018 Apr; 13(4):e0191926. PMID: 29617360
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells. Anti-CTLA-4 antibodies enhance tumor-specific immunity through a variety...
3.
Damasceno L, Ritter G, Batt C
Protein Expr Purif . 2017 Apr; 134:72-81. PMID: 28389350
The trematode Schistosoma mansoni Sm14 antigen was expressed in the yeast Pichia pastoris and secreted into the culture medium at yields of approximately 250 mg L. Sm14 belongs to a...
4.
Veit J, Heine D, Thierauf J, Lennerz J, Shetty S, Schuler P, et al.
Head Neck . 2016 Feb; 38(7):1008-16. PMID: 26874246
Background: Adenoid cystic carcinoma (ACC) of the head and neck is a rare but highly malignant tumor. Cancer-testis antigens (CTAs) represent an immunogenic family of cancer-specific proteins and thus represent...
5.
Zanzonico P, Carrasquillo J, Pandit-Taskar N, ODonoghue J, Humm J, Smith-Jones P, et al.
Eur J Nucl Med Mol Imaging . 2015 Jul; 42(11):1700-1706. PMID: 26194713
Purpose: The molecular specificity of monoclonal antibodies (mAbs) directed against tumor antigens has proven effective for targeted therapy of human cancers, as shown by a growing list of successful antibody-based...
6.
Dos Santos L, Galvao-Filho B, de Faria P, Junqueira C, Santos Dutra M, Teixeira S, et al.
Cancer Immunol Immunother . 2014 Nov; 64(3):311-23. PMID: 25403749
The development of cancer immunotherapy has long been a challenge. Here, we report that prophylactic vaccination with a highly attenuated Trypanosoma cruzi strain expressing NY-ESO-1 (CL-14-NY-ESO-1) induces both effector memory...
7.
Tsuji T, Sabbatini P, Jungbluth A, Ritter E, Pan L, Ritter G, et al.
Cancer Immunol Res . 2014 Apr; 1(5):340-50. PMID: 24777970
Vaccination of patients with ovarian cancer with overlapping long peptides (OLP) from cancer-testis antigen NY-ESO-1 and poly-ICLC in Montanide-ISA-51 (Montanide) was found to consistently induce integrated immune responses (antibody, CD4(+),...
8.
Odunsi K, Matsuzaki J, James S, Mhawech-Fauceglia P, Tsuji T, Miller A, et al.
Cancer Immunol Res . 2014 Feb; 2(1):37-49. PMID: 24535937
The cancer-testis/cancer-germline antigen NY-ESO-1 is a vaccine target in epithelial ovarian cancer (EOC), but its limited expression is a barrier to vaccine efficacy. As NY-ESO-1 is regulated by DNA methylation,...
9.
Laban S, Atanackovic D, Luetkens T, Knecht R, Busch C, Freytag M, et al.
Int J Cancer . 2014 Feb; 135(5):1142-52. PMID: 24482145
The prognosis of head and neck squamous cell carcinoma (HNSCC) patients remains poor. The identification of high-risk subgroups is needed for the development of custom-tailored therapies. The expression of cancer-testis...
10.
Reis B, Jungbluth A, Frosina D, Holz M, Ritter E, Nakayama E, et al.
Clin Cancer Res . 2013 Oct; 19(22):6112-25. PMID: 24081977
Purpose: Human endogenous retroviruses (HERV) encode 8% of the human genome. While HERVs may play a role in autoimmune and neoplastic disease, no mechanistic association has yet been established. We...